{"id":77075,"date":"2026-08-28T21:05:40","date_gmt":"2026-08-28T13:05:40","guid":{"rendered":"https:\/\/flcube.com\/?p=77075"},"modified":"2026-08-28T21:05:41","modified_gmt":"2026-08-28T13:05:41","slug":"hutchmeds-fanregratinib-wins-nmpa-conditional-approval-for-fgfr2-rearranged-intrahepatic-cholangiocarcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77075","title":{"rendered":"HutchMed&#8217;s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>HutchMed (China) Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/HCM:NASDAQ\">NASDAQ: HCM<\/a>, <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/0013:HKG\">HKG: 0013<\/a>) announced that the New Drug Application (NDA) for <strong>fanregratinib (HMPL-453)<\/strong> has been conditionally approved by the <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of adult patients with advanced, metastatic, or unresectable <strong>intrahepatic cholangiocarcinoma (ICC)<\/strong> who have previously received systemic therapy and harbor <strong>fibroblast growth factor receptor (FGFR) 2<\/strong> fusions or rearrangements. The drug will be marketed under the brand name <strong>ATLED<\/strong>, adding a precision-oncology option to a rare and difficult-to-treat biliary cancer.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr><tr><td>Approval Type<\/td><td>Conditional approval of New Drug Application (NDA)<\/td><\/tr><tr><td>Product<\/td><td><strong>Fanregratinib (HMPL-453)<\/strong>, marketed as <strong>ATLED<\/strong><\/td><\/tr><tr><td>Indication<\/td><td>Adults with advanced\/metastatic\/unresectable <strong>ICC<\/strong> with <strong>FGFR2<\/strong> fusions or rearrangements, previously treated with systemic therapy<\/td><\/tr><tr><td>Date<\/td><td>28 Aug 2026<\/td><\/tr><tr><td>Rights<\/td><td><strong>HutchMed<\/strong> holds worldwide rights to <strong>fanregratinib<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Fanregratinib (HMPL-453)<\/strong>, a novel, highly selective, and potent inhibitor of <strong>FGFR 1, 2, and 3<\/strong><\/li>\n\n\n\n<li><strong>Target Rationale:<\/strong> Aberrant FGFR signaling has been identified as a driver of tumor growth, promotion of angiogenesis, and resistance to anticancer therapies<\/li>\n\n\n\n<li><strong>Biomarker Strategy:<\/strong> Abnormal FGFR genetic alterations are considered drivers of tumor cell proliferation in various solid tumors; <strong>FGFR2<\/strong> fusions\/rearrangements define the approved ICC population<\/li>\n\n\n\n<li><strong>Brand Name:<\/strong> <strong>ATLED<\/strong><\/li>\n\n\n\n<li><strong>Ownership:<\/strong> <strong>HutchMed<\/strong> currently holds worldwide rights, preserving full global commercial and partnership flexibility<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-context-intrahepatic-cholangiocarcinoma\" class=\"wp-block-heading\">Disease Context \u2013 Intrahepatic Cholangiocarcinoma<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Significance<\/th><\/tr><\/thead><tbody><tr><td>Disease Type<\/td><td>Rare, aggressive biliary tract cancer arising in the liver<\/td><\/tr><tr><td>Treatment Landscape<\/td><td>Limited options after failure of prior systemic therapy<\/td><\/tr><tr><td>Biomarker Subset<\/td><td>FGFR2 fusions\/rearrangements identify a molecularly defined subgroup amenable to targeted therapy<\/td><\/tr><tr><td>Clinical Need<\/td><td>Precision medicine options remain scarce, making FGFR inhibition a key therapeutic strategy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">By targeting the FGFR pathway that drives tumor proliferation in this molecularly defined subset, <strong>ATLED<\/strong> addresses a second-line setting where chemotherapy options offer limited benefit. The conditional approval pathway reflects the high unmet need in previously treated <strong>FGFR2<\/strong>-rearranged ICC and provides patients with earlier access while confirmatory obligations are fulfilled.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Precision Oncology Entry:<\/strong> The approval positions <strong>HutchMed<\/strong> in the rapidly growing FGFR-inhibitor niche, where biomarker-defined prescribing supports premium pricing and targeted commercialization<\/li>\n\n\n\n<li><strong>Worldwide Rights Value:<\/strong> Retaining global rights to <strong>fanregratinib<\/strong> gives <strong>HutchMed<\/strong> (NASDAQ: HCM, HKG: 0013) leverage for international partnerships or out-licensing beyond China<\/li>\n\n\n\n<li><strong>Differentiated Selectivity:<\/strong> The highly selective FGFR 1\/2\/3 inhibition profile is a potential competitive lever against less selective pan-FGFR agents in the class<\/li>\n\n\n\n<li><strong>Portfolio Expansion:<\/strong> <strong>ATLED<\/strong> broadens <strong>HutchMed&#8217;s<\/strong> oncology portfolio alongside its existing commercialized therapies, reinforcing the company&#8217;s transition toward innovation-driven revenue<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief contains forward-looking statements regarding regulatory conditions, commercialization, and partnership potential. Conditional approval may be subject to post-marketing requirements. Actual results may differ materially. Not investment advice.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":77077,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,1105,285,1104,15],"class_list":["post-77075","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-hkg-0013","tag-hutchmed","tag-nasdaq-hcm","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>HutchMed&#039;s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for fanregratinib (HMPL-453) has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) who have previously received systemic therapy and harbor fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements. The drug will be marketed under the brand name ATLED, adding a precision-oncology option to a rare and difficult-to-treat biliary cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77075\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HutchMed&#039;s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma\" \/>\n<meta property=\"og:description\" content=\"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for fanregratinib (HMPL-453) has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) who have previously received systemic therapy and harbor fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements. The drug will be marketed under the brand name ATLED, adding a precision-oncology option to a rare and difficult-to-treat biliary cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77075\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-28T13:05:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T13:05:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2807.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HutchMed&#8217;s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma\",\"datePublished\":\"2026-08-28T13:05:40+00:00\",\"dateModified\":\"2026-08-28T13:05:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075\"},\"wordCount\":454,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2807.webp\",\"keywords\":[\"Cancer\",\"HKG: 0013\",\"HutchMed\",\"NASDAQ: HCM\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77075#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77075\",\"name\":\"HutchMed's Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2807.webp\",\"datePublished\":\"2026-08-28T13:05:40+00:00\",\"dateModified\":\"2026-08-28T13:05:41+00:00\",\"description\":\"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for fanregratinib (HMPL-453) has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) who have previously received systemic therapy and harbor fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements. The drug will be marketed under the brand name ATLED, adding a precision-oncology option to a rare and difficult-to-treat biliary cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77075\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2807.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/2807.webp\",\"width\":1080,\"height\":608,\"caption\":\"HutchMed's Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77075#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HutchMed&#8217;s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HutchMed's Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for fanregratinib (HMPL-453) has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) who have previously received systemic therapy and harbor fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements. The drug will be marketed under the brand name ATLED, adding a precision-oncology option to a rare and difficult-to-treat biliary cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77075","og_locale":"en_US","og_type":"article","og_title":"HutchMed's Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","og_description":"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for fanregratinib (HMPL-453) has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) who have previously received systemic therapy and harbor fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements. The drug will be marketed under the brand name ATLED, adding a precision-oncology option to a rare and difficult-to-treat biliary cancer.","og_url":"https:\/\/flcube.com\/?p=77075","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-28T13:05:40+00:00","article_modified_time":"2026-08-28T13:05:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2807.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77075#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77075"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HutchMed&#8217;s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","datePublished":"2026-08-28T13:05:40+00:00","dateModified":"2026-08-28T13:05:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77075"},"wordCount":454,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=77075#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2807.webp","keywords":["Cancer","HKG: 0013","HutchMed","NASDAQ: HCM","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77075#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77075","url":"https:\/\/flcube.com\/?p=77075","name":"HutchMed's Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=77075#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=77075#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2807.webp","datePublished":"2026-08-28T13:05:40+00:00","dateModified":"2026-08-28T13:05:41+00:00","description":"HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced that the New Drug Application (NDA) for fanregratinib (HMPL-453) has been conditionally approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma (ICC) who have previously received systemic therapy and harbor fibroblast growth factor receptor (FGFR) 2 fusions or rearrangements. The drug will be marketed under the brand name ATLED, adding a precision-oncology option to a rare and difficult-to-treat biliary cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77075#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77075"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=77075#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2807.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2807.webp","width":1080,"height":608,"caption":"HutchMed's Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77075#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HutchMed&#8217;s Fanregratinib Wins NMPA Conditional Approval for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2807.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77075"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77075\/revisions"}],"predecessor-version":[{"id":77078,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77075\/revisions\/77078"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/77077"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}